Printer Friendly

DEPRENYL USA REPORTS RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDING JUNE 30, 1992

 DEPRENYL USA REPORTS RESULTS FOR SECOND QUARTER
 AND SIX MONTHS ENDING JUNE 30, 1992
 PARSIPANNY, N.J., Aug. 13 /PRNewswire/ -- Deprenyl USA, Inc. (NASDAQ: DUSA), a development stage pharmaceutical company, today reported revenues of $249,341 for the three months ended June 30, 1992 and $428,903 for the six months, year to date. Revenue was primarily interest income earned on the proceeds of the company's initial public offering in late January, 1992. Expenses of $413,978 in the second quarter, and $869,130 for the first half of 1992, reflect primarily the company's investment in its new drug development program for ALA Photodynamic Therapy (PDT), initially for the treatment of superficial skin cancers and pre-cancers. Because of these planned expenses, the company had a net loss for the second quarter of $164,637, equal to $0.03 per share on 5,075,000 average shares outstanding. For the first half, the loss was $440,227 or $0.09 per share on 4,806,456 average shares outstanding.
 In announcing the results, Dr. Geoffrey Shulman, president, said, "Operations are proceeding according to our business plan and budgeting expectations. I am pleased to report that we are maintaining the dermatology development program schedules, for both the light source and drug dosage form, working with Medicis Pharmaceutical Corporation and our consultants."
 The company also reported it expects to be in a position to file an investigational new drug (IND) application with the United States Food and Drug Administration (FDA) in late 1992, following which, clinical trials will begin.
 "Over the past quarter," Shulman added, "besides our progress on ALA PDT for dermatology, the company reported achievements which add significantly to our potential in the development and marketing of prescription pharmaceuticals. On April 23, 1992, we announced the signing of a new research agreement between the company and Queen's University at Kingston, Ontario, which focuses on development of ALA PDT as a non-surgical alternative to hysterectomy for women with excessive uterine bleeding."
 "In June, we reported that researchers at the National Medical Laser Center, London, found the treatment (ALA PDT) destroyed cancer cells without significantly affecting normal tissue in a pre-clinical model of bowel cancer. Their findings, published in the June 1992 issue of the British Journal of Cancer, show that the potential for this technique is very considerable."
 This was followed by a world meeting on Photodynamic Therapy in Milan, Italy, where a number of papers were presented on ALA PDT. These not only reinforced its usefulness in the treatment of superficial skin cancers, but also continued to open up new horizons on the use of ALA PDT for diagnosis and treatment of a variety of internal cancers, and certain non-cancerous conditions.
 Also in June, we announced that the Australian patent application for ALA PDT was allowed. Because Australians suffer from one of the highest rates of skin cancer in the world, this will be an important international market for ALA PDT, upon regulatory approval.
 Lastly, the company is in the process of finalizing an option on a new group of compounds for photodynamic therapy, which have shown strong anti-cancer experimental activity. These could complement ALA PDT in the future, and allow treatment of larger tumors.
 "Looking ahead", Shulman said, "during the remainder of 1992, we expect to be reporting further progress on drug development and corporate growth programs, as we continue to build Deprenyl USA's presence in prescription pharmaceuticals."
 Deprenyl USA, Inc. (DUSA) is a development stage company established to develop prescription pharmaceutical products for all markets, including the United States and Canada, primarily in the field of photodynamic therapy, which combines the use of a pharmaceutical product such as ALA, with exposure to light, to induce a therapeutic effect. DUSA is developing ALA PDT, initially for the treatment of certain skin conditions, including basal cell carcinomas, pre-cancerous actinic keratoses, and psoriasis. The company is based in Parsipanny, N.J., with operations also conducted from facilities in Toronto.
 DEPRENYL USA, INC.
 (All figures in U.S. Dollars - Unaudited)
 Period ended June 30, 1992 Three months Six months
 Revenues 249,341 428,903
 Operating expenses 413,978 869,130
 Net loss (164,637) (440,227)
 Loss per share (0.03) (0.09)
 -0- 8/13/92
 /CONTACT: Geoffrey Shulman, president and CEO, or Edward L.


Foster, CFO, (Toronto) 416-537-1070, or Joseph P. Castelli, vice president, (New Jersey) 201-299-9070, all Deprenyl USA; or Irving L. Straus of Straus Corporate Communications, 212-768-2477, for Deprenyl USA/
 (DUSA) CO: Deprenyl USA, Inc. ST: New Jersey IN: MTC SU: ERN


SM-KW -- NY021 -- 9553 08/13/92 10:58 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 13, 1992
Words:762
Previous Article:MONAGHAN ANNOUNCES DETROIT TIGERS SALE
Next Article:NATIONAL TECHTEAM, INC. ANNOUNCES AGREEMENT FOR ACQUISITION OF UNIBASE, INC.
Topics:


Related Articles
DEPRENYL RESEARCH LIMITED REPORTS EARNINGS
THE IMMUNE RESPONSE CORPORATION ANNOUNCES SECOND QUARTER 1992 FINANCIAL RESULTS
VESTAR REPORTS 1992 SECOND QUARTER RESULTS; REVENUES UP 125 PERCENT WITH CONTINUED PROFITABILITY
RIBI IMMUNOCHEM REPORTS 1992 SECOND-QUARTER FINANCIAL RESULTS
JONES MEDICAL REPORTS RECORD SECOND QUARTER EARNINGS PER SHARE OF 9 CENTS UP 29 PERCENT
DEPRENYL USA, INC. REPORTS RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPT. 30, 1992; EXPECTS TO FILE ITS FIRST INVESTIGATIONAL NEW DRUG
DEPRENYL USA REPORTS YEAR END 1992 RESULTS; CONFIRMS ALA PHOTODYNAMIC DEVELOPMENT ON SCHEDULE; PROPOSES NAME CHANGE TO DUSA PHARMACEUTICALS
DEPRENYL RESEARCH REPORTS EARNINGS
DEPRENYL USA REPORTS FIRST QUARTER RESULTS ON PLAN INITIAL CLINICAL TRIALS PROCEEDING ON SCHEDULE
MEDCO RESEARCH REPORTS SECOND QUARTER FINANCIAL RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters